Cargando…

Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant

OBJECTIVES: Comprehensive breast cancer (BC) risk models integrating effects of genetic (GRF) and non-genetic risk factors (NGRF) may refine BC prevention recommendations. We explored the perceived information received on BC risk factors, and related characteristics, in female relatives of women wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brédart, Anne, De Pauw, Antoine, Anota, Amélie, Tüchler, Anja, Dick, Julia, Müller, Anita, Kop, Jean-Luc, Rhiem, Kerstin, Schmutzler, Rita, Devilee, Peter, Stoppa-Lyonnet, Dominique, Dolbeault, Sylvie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403756/ https://www.ncbi.nlm.nih.gov/pubmed/34455229 http://dx.doi.org/10.1016/j.breast.2021.08.011

Ejemplares similares

Assessment of psychosocial difficulties by genetic clinicians and distress in women at high risk of breast cancer: a prospective study
por: Brédart, Anne, et al.
Publicado: (2022)

Genetic clinicians' confidence in BOADICEA comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: A prospective study
por: Brédart, Anne, et al.
Publicado: (2022)

Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study
por: Brédart, Anne, et al.
Publicado: (2019)

Patient-Centered Care in Breast Cancer Genetic Clinics
por: Brédart, Anne, et al.
Publicado: (2018)

Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study
por: Dick, Julia, et al.
Publicado: (2022)

Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer
por: Brédart, A, et al.
Publicado: (2013)

Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries
por: Brédart, Anne, et al.
Publicado: (2017)

Clinicians’ use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey
por: Brédart, Anne, et al.
Publicado: (2018)

Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development
por: Huo, Yanying, et al.
Publicado: (2021)

PALB2 (partner and localizer of BRCA2)
por: Hanenberg, Helmut, et al.
Publicado: (2018)

Plasticity of BRCA2 Function in Homologous Recombination: Genetic Interactions of the PALB2 and DNA Binding Domains
por: Siaud, Nicolas, et al.
Publicado: (2011)

Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2
por: Boonen, Rick A. C. M., et al.
Publicado: (2019)

PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response
por: Simhadri, Srilatha, et al.
Publicado: (2018)

Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2
por: Hartford, Suzanne A., et al.
Publicado: (2016)

Estrogen receptor transcription and transactivation: Genetic modifiers of cancer risks conferred by BRCA1 and BRCA2
por: Devilee, P
Publicado: (2001)

Surgery for BRCA, TP53 and PALB2: a literature review
por: Song, Chin-Vern, et al.
Publicado: (2018)

Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2021)

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
por: Seeber, Andreas, et al.
Publicado: (2020)

Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era
por: Macedo, Gabriel S., et al.
Publicado: (2019)

Compromised BRCA1-PALB2 interaction is associated with breast cancer risk
por: Foo, Tzeh Keong, et al.
Publicado: (2017)

Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review
por: Krassuski, Lisa Marlene, et al.
Publicado: (2021)

Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families
por: Pylkäs, Katri, et al.
Publicado: (2008)

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
por: Wojcik, P., et al.
Publicado: (2016)

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls
por: Behl, Supriya, et al.
Publicado: (2020)

Long-term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report
por: Bredow, Kathrin, et al.
Publicado: (2022)

Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient
por: Kahn, Ryan, et al.
Publicado: (2016)

The biological effects and clinical implications of BRCA mutations: where do we go from here?
por: Stoppa-Lyonnet, Dominique
Publicado: (2016)

Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
por: Takeuchi, Shoko, et al.
Publicado: (2018)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study
por: Zhen, David B., et al.
Publicado: (2014)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2023)

Coping Self-Efficacy and Its Relationship with Psychological Morbidity after Genetic Test Result Disclosure: Results from Cancer-Unaffected BRCA1/2 Mutation Carriers
por: Isselhard, Anna, et al.
Publicado: (2023)

Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada
por: Hartley, Taila, et al.
Publicado: (2014)

Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers
por: Hamid, Abdulaziz B., et al.
Publicado: (2022)

Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis
por: Tsyganov, Matvey M., et al.
Publicado: (2023)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report
por: Lopez-Perolio, Irene, et al.
Publicado: (2019)

Should Preimplantation Genetic Testing (PGT) Systematically Be Proposed to BRCA Pathogenic Variant Carriers?
por: Laot, Lucie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_50e4pdgdta8mk3npdn4b80eb77